Market Overview:
The global glioblastoma multiforme (GBM) therapeutics market is expected to register a CAGR of 10.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of GBM and rising demand for targeted drug therapies and radiation therapies. Based on type, the global glioblastoma multiforme (GBM) therapeutics market is segmented into chemotherapies, targeted drug therapies, and radiation therapies. Chemotherapies are further classified into alkylating agents, antimetabolites, topoisomerase inhibitors, and others. Targeted drug therapy is further sub-segmented into EGFR inhibitors/tyrosine kinase inhibitors (TKIs), VEGF inhibitors/angiogenesis inhibitors (AIs), mTOR inhibitors/PI3K pathway blockers (IKKs), BRAF inhibitor & MEK inhibitor combinations therapy; while radiation therapy is sub-segmented into external beam radiotherapy & brachytherapy. Based on application, the global glioblastoma multiforme therapeutics market is segmented into hospitals clinics & other end users such as research institutes & academic medical centers). Hospitals held a dominant share in 2017 owing to increased number of patients diagnosed with GBM in this setting across regions such as North America and Europe.
Product Definition:
Glioblastoma multiforme (GBM) is an aggressive type of brain tumor that can be difficult to treat. GBM Therapeutics are drugs or therapies used to treat Glioblastoma Multiforme. They may include surgery, radiation therapy, and chemotherapy.
ChemOthersapy:
Chemotherapeutics is a drug class that includes drugs such as carmustine, vincristine, lomustine, procarbazine, and temozolomide. Chemotherapy refers to the use of drugs or chemical substances for the treatment of cancer.
Targeted Drug Therapy:
Targeted drug therapy is a form of medication that delivers only the targeted chemical to the brain tumor and leaves other parts of the body unaffected. The main aim of this type of treatment is to reduce or eliminate side effects caused by the medication. This helps in increasing patient compliance, as well as improves safety by reducing dosage levels and adverse reactions.
Application Insights:
The others application segment held the largest share of the global market in 2017. This can be attributed to the increasing number of patients opting for surgery over radiation and chemotherapy as an alternative treatment option. According to a study published by NCBI, in 2018, around 60% of glioblastoma patients were treated with surgery only while 40% were treated with both chemotherapeutic drugs and radiotherapy. The others segment includes hospitals and clinics that are outside conventional healthcare facilities such as hospitals or diagnostic centers. Hospitals & clinics are generally equipped with advanced diagnostics equipment including MRI scanners which enable accurate diagnosis at lower cost compared to other imaging techniques such as CT or X-ray scan images used before 2014 when these machines were introduced into developing countries like India, China etc.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in incidence rates of GBM coupled with an increase in awareness about available treatment options. In addition, favorable reimbursement policies for glioblastoma multiforme treatments and increasing healthcare expenditure are some other factors contributing to the growth of this regional market.
Asia Pacific is expected to witness lucrative growth over the forecast period due to rising disposable income, improving healthcare infrastructure and growing patient awareness regarding availability of effective treatment methods for GBM. Moreover, an increase in investment by pharmaceutical companies for R&D on novel drug molecules will also drive this regional market during the forecast period.
The key players operating within Asia Pacific include Pfizer Inc.; Merck & Co., Inc.; Celgene Corporation; AbbVie Inc.
Growth Factors:
- Increasing incidence of glioblastoma multiforme (GBM)
- Rising demand for better treatment options for glioblastoma multiforme (GBM) patients
- Growing awareness about glioblastoma multiforme (GBM) and its treatment options
- Technological advancements in the field of glioblastoma multiforme (GBM) therapeutics
- increasing investment in research and development of novel therapies for glioblastoma multiforme (GBM)
Scope Of The Report
Report Attributes
Report Details
Report Title
Glioblastoma Multiforme (GBM) Therapeutics Market Research Report
By Type
ChemOthersapy, Targeted Drug Therapy, Radiation Therapy
By Application
Hospitals, Clinics, Others
By Companies
Merck, Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceuticals, Teva Pharmaceutical, Emcure Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Glioblastoma Multiforme (GBM) Therapeutics Market Report Segments:
The global Glioblastoma Multiforme (GBM) Therapeutics market is segmented on the basis of:
Types
ChemOthersapy, Targeted Drug Therapy, Radiation Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Roche
- Arbor Pharmaceuticals
- Pfizer
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Sun Pharmaceuticals
- Teva Pharmaceutical
- Emcure Pharmaceuticals
Highlights of The Glioblastoma Multiforme (GBM) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ChemOthersapy
- Targeted Drug Therapy
- Radiation Therapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glioblastoma Multiforme (GBM) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glioblastoma multiforme (GBM) is a type of brain cancer that is very difficult to treat. There are currently no approved treatments for GBM. However, there are several investigational drugs being developed for GBM treatment. Some of these drugs have shown some promise in clinical trials, but they still need to be tested further before they can be approved by the FDA for use in patients with GBM.
Some of the major companies in the glioblastoma multiforme (gbm) therapeutics market are Merck, Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceuticals, Teva Pharmaceutical, Emcure Pharmaceuticals.
The glioblastoma multiforme (gbm) therapeutics market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glioblastoma Multiforme (GBM) Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Glioblastoma Multiforme (GBM) Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Glioblastoma Multiforme (GBM) Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Glioblastoma Multiforme (GBM) Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size & Forecast, 2020-2028 4.5.1 Glioblastoma Multiforme (GBM) Therapeutics Market Size and Y-o-Y Growth 4.5.2 Glioblastoma Multiforme (GBM) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ChemOthersapy
5.2.2 Targeted Drug Therapy
5.2.3 Radiation Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glioblastoma Multiforme (GBM) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glioblastoma Multiforme (GBM) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ChemOthersapy
9.6.2 Targeted Drug Therapy
9.6.3 Radiation Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ChemOthersapy
10.6.2 Targeted Drug Therapy
10.6.3 Radiation Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ChemOthersapy
11.6.2 Targeted Drug Therapy
11.6.3 Radiation Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ChemOthersapy
12.6.2 Targeted Drug Therapy
12.6.3 Radiation Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ChemOthersapy
13.6.2 Targeted Drug Therapy
13.6.3 Radiation Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glioblastoma Multiforme (GBM) Therapeutics Market: Competitive Dashboard
14.2 Global Glioblastoma Multiforme (GBM) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Roche
14.3.3 Arbor Pharmaceuticals
14.3.4 Pfizer
14.3.5 AbbVie
14.3.6 Amgen
14.3.7 Bristol-Myers Squibb
14.3.8 Sun Pharmaceuticals
14.3.9 Teva Pharmaceutical
14.3.10 Emcure Pharmaceuticals